Asset
REC-2282
Recursion Pharmaceuticals Inc. Class A Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05130866 | phase2_3 | terminated | 2022-06-20 | 2025-08-18 | Recursion Pharmaceuticals Inc. | Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas |
FDA applications (0)
This company has no applications containing this asset.